Logo image of COEP

COEPTIS THERAPEUTICS HOLDING (COEP) Stock Fundamental Analysis

NASDAQ:COEP - Nasdaq - US19207A2078 - Common Stock - Currency: USD

9.47  -0.03 (-0.32%)

Fundamental Rating

1

Taking everything into account, COEP scores 1 out of 10 in our fundamental rating. COEP was compared to 558 industry peers in the Biotechnology industry. COEP may be in some trouble as it scores bad on both profitability and health. COEP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COEP had negative earnings in the past year.
In the past year COEP has reported a negative cash flow from operations.
In the past 5 years COEP always reported negative net income.
In the past 5 years COEP always reported negative operating cash flow.
COEP Yearly Net Income VS EBIT VS OCF VS FCFCOEP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -260.16%, COEP is doing worse than 91.81% of the companies in the same industry.
The Return On Equity of COEP (-486.73%) is worse than 77.05% of its industry peers.
Industry RankSector Rank
ROA -260.16%
ROE -486.73%
ROIC N/A
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COEP Yearly ROA, ROE, ROICCOEP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COEP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COEP Yearly Profit, Operating, Gross MarginsCOEP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, COEP has more shares outstanding
COEP has less shares outstanding than it did 5 years ago.
The debt/assets ratio for COEP has been reduced compared to a year ago.
COEP Yearly Shares OutstandingCOEP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
COEP Yearly Total Debt VS Total AssetsCOEP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -18.19, we must say that COEP is in the distress zone and has some risk of bankruptcy.
COEP has a worse Altman-Z score (-18.19) than 82.21% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that COEP is not too dependend on debt financing.
COEP has a worse Debt to Equity ratio (0.03) than 60.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -18.19
ROIC/WACCN/A
WACCN/A
COEP Yearly LT Debt VS Equity VS FCFCOEP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

COEP has a Current Ratio of 1.76. This is a normal value and indicates that COEP is financially healthy and should not expect problems in meeting its short term obligations.
COEP's Current ratio of 1.76 is on the low side compared to the rest of the industry. COEP is outperformed by 78.47% of its industry peers.
A Quick Ratio of 1.76 indicates that COEP should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.76, COEP is not doing good in the industry: 77.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.76
COEP Yearly Current Assets VS Current LiabilitesCOEP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

3

3. Growth

3.1 Past

COEP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.79%, which is quite impressive.
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.76% on average over the next years. This is quite good.
The Revenue is expected to grow by 19.70% on average over the next years. This is quite good.
EPS Next Y98.47%
EPS Next 2Y41.07%
EPS Next 3Y25.78%
EPS Next 5Y18.76%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%

3.3 Evolution

COEP Yearly Revenue VS EstimatesCOEP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2027 2028 2029 2030 10M 20M 30M 40M 50M
COEP Yearly EPS VS EstimatesCOEP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

COEP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COEP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COEP Price Earnings VS Forward Price EarningsCOEP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COEP Per share dataCOEP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as COEP's earnings are expected to grow with 25.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.07%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COEP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COEPTIS THERAPEUTICS HOLDING

NASDAQ:COEP (7/11/2025, 8:01:24 PM)

9.47

-0.03 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners4.33%
Inst Owner Change0%
Ins Owners15.6%
Ins Owner Change0%
Market Cap33.24M
Analysts43.33
Price TargetN/A
Short Float %0.97%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1072.39%
Min EPS beat(2)-2154.9%
Max EPS beat(2)10.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.71
P/tB 7.71
EV/EBITDA N/A
EPS(TTM)-17.58
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -260.16%
ROE -486.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.8%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.76
Altman-Z -18.19
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
EPS Next Y98.47%
EPS Next 2Y41.07%
EPS Next 3Y25.78%
EPS Next 5Y18.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%
EBIT growth 1Y64.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.72%
EBIT Next 3Y-3%
EBIT Next 5Y14.87%
FCF growth 1Y-86.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.79%
OCF growth 3YN/A
OCF growth 5YN/A